CNR1 and atherosclerosis: In the last decade, solid evidence has pointed to the two main receptors that bind to and mediate the biological activity of exogenous (plant-derived or synthetic) cannabinoids and of their endogenous counterparts (endocannabinoids), namely type-1 and type-2 cannabinoid receptors (CB1R and CB2R), as relevant players in atherosclerosis, endowed with pro-atherogenic [9, 10] and anti-atherogenic effects respectively [11–14].